Management options for established chemotherapy-induced peripheral neuropathy
Deirdre R. Pachman(Mayo Clinic), Charles L. Loprinzi(Mayo Clinic in Arizona), D. Storey(Western General Hospital), Pascal Jean‐Pierre(University of Miami), James C. Watson(Vanderbilt University), Susanne Koeppen(University of Duisburg-Essen), Herwig Strik(Philipps University of Marburg), Marie Fallon(University of Edinburgh), Jayesh Kamath(University of Connecticut), Alexandre Chan(University of California, Irvine), Larry Broadfield(Cancer Care Nova Scotia), Kavita D. Chandwani(University of Rochester Medicine), Christopher Steer(Albury Wodonga Health), Yin Ting Cheung(Chinese University of Hong Kong), Maryam B. Lustberg(Yale Cancer Center), Judith A. Paice(Northwestern University), Jeong Hoon Oh(The University of Texas MD Anderson Cancer Center), Nina D. Wagner‐Johnston(Sidney Kimmel Comprehensive Cancer Center)
Cited by 51
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Cancer-Related Fatigue, Version 2.2015
|Journal of the National Comprehensive Cancer Network|2015|951
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
|Annals of Oncology|2018|874